AI brief of an SEC Form 8-K · DocGo Inc. (DCGO)

DocGo enters $50 million-plus amended credit deal with Perceptive, issues warrant

Mixed Impact 4 of 5 financing Written later

DocGo and its subsidiaries entered into an amended and restated credit agreement on October 1, 2026, with Perceptive Credit Holdings IV as administrative agent, replacing a prior Citibank-led revolving facility that was terminated the same day. The new term loans total $102 million in committed facilities, with a stated maturity of December 6, 2029, and the company issued a warrant for 4,000,000 shares at $0.5039 per share as part of the deal, which could dilute existing holders.

Key points

  • Term loans include $52 million continued from prior debt, $12.5 million new Term Loan B, $12.5 million Term Loan C tied to the Merger, and $25 million delayed draw Term Loan D
  • Term SOFR with a 3.50% floor plus a 7.50% margin; maturity December 6, 2029
  • Warrant to purchase 4,000,000 common shares at $0.5039 per share, fully vested, exercisable through the tenth anniversary of October 1, 2026
  • Ambulnz began managing Hicuity's non-clinical operations effective October 1, 2026; 98,992,347 common shares were outstanding as of October 1, 2026

The filing

CompanyDocGo Inc. (DCGO)
Form8-K, current report
Filed with the SECOct 5, 2026, 6:32 AM ET
Accession number0001628280-26-064740

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.